Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)

Clinical Lung Cancer

Volumn 12, Issue 3, 2011, Pages 172-179

  Cedrés, Susana ^a   Nuñez, Isaac ^a   Longo, Marina ^a   Martinez, Pablo ^a   Checa, Eva ^a   Torrejón, Davis ^a   Felip, Enriqueta ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Prognostic factor; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; BRAIN METASTASIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; THORAX SURGERY; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA;

EID: 79959610405     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.019     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposal for revision of the T, N and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007; 2:694-705. (Pubitemid 47357521)
3. Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemo-naive patients with advanced non-small cell lung cancer treated with third generation chemotherapy regimen based on eastern cooperative oncology group data. J Clin Oncol 2005; 23:175-83. (Pubitemid 41702636)
4. Ford CH, Stokes HJ, Newman CE. Carcynoembrionic antigen and prognosis after radical surgery for lung cancer: immunocytochemical localization and serum levels. Br J Cancer 1981; 44:145-53. (Pubitemid 11039569)
5. Dent PB, McCulloch PB, Wesley-James O, et al. Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma. Cancer 1978; 42:1484-91. (Pubitemid 9038280)
6. Vincent RG, Chu TM, Fergen TB, et al. Carcinoembryonic antigen in 228 patients with carcinoma of the lung. Cancer 1975; 36:2069-76.
7. Hotta K, Segawa Y, Takigawa N, et al. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical stage I patients with non-small cell lung cancer. Anticancer Res 2000; 20:2177-80. (Pubitemid 30636204)
8. Rubins JB, Dunitz J, Rubins HB, et al. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 1998; 116:412-6. (Pubitemid 28400171)
9. Díez M, Torres A, Maestro ML, et al. Prediction of survival and recurrence by serum and cytosolic levels of CEA, ca 125 and SCC antigens in resectable non-small cell lung cancer. Br J Cancer 1996; 73:1248-54. (Pubitemid 26162341)
10. Takamochi K, Nagai K, Suzuki K, et al. Clinical predictors of N2 disease in nonsmall cell lung cancer. Chest 2000; 117:1577-82. (Pubitemid 30413347)
11. Sawabata N, Maeda H, Yokota S, et al. Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA NSCLC. Subnormal levels as an indicator of favourable prognosis. Cancer 2004; 101:803-9. (Pubitemid 39030938)
12. Molina R, Zanon G, Filella X, et al. Use of serial carcinoembryonic antigen and Ca15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36:41-8.
13. Meyerhardt JA, Mayer RJ. Follow-up strategies after curative resection of colorectal cancer. Semin Oncol 2003; 30:349-60. (Pubitemid 36706559)
14. Molina R, Filella X, Augé JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumor Biol 2003; 24:209-18. (Pubitemid 37500571)
15. Moll R, Franke WW, Schiller DJ, et al. The catalog of human cytokeratins: pattern of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31:11-24. (Pubitemid 13215192)
16. Medeiros LR, Rossa DD, da Rosa MI, et al. Accuracy of Ca125 in the diagnosis of ovarian tumors: a quantitative systemic review. Eur J Obstet Gynecol Reprod Biol 2009; 142:99-105.
17. Giovanella L, Piantanida R, Ceriani L, et al. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis. Int J Biol Markers 1997; 12:22-6. (Pubitemid 27229453)
18. Diez M, Torres A, Ortega L, et al. Value of serum neuronspecific enolase in non small cell lung cancer. Oncology 1993; 50:127-31. (Pubitemid 23098732)
19. Greene FL. American Joint Committee on Cancer, American Cancer Society, AJCC Cancer Staging Manual. 6th edition. New York: Springer Verlag, 2002.
20. Margolis ML, Hyzy JB, Schenken LL, et al. Serum tumor markers in non small cell lung cancer. A comparative analysis. Cancer 1994; 73:605-9. (Pubitemid 24046600)
21. Kulpa J, Wojcik E, Radkowski A, et al. CYFRA 21-1, TPA-M, TPS, SCC-AG and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Res 2000; 20:5035-40. (Pubitemid 32319075)
22. Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002; 69:25-9. (Pubitemid 34158384)
23. Kulpa J, Wójcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002; 48:11:1931-7. (Pubitemid 35222751)
24. Ardizzoni A, Cafferata M, Tiseo M, et al. Decline serum carcinomebryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non small cell lung cancer. Cancer 2006; 107:2842-9. (Pubitemid 44937038)
25. Moro D, Villemain D, Vuillez JP, et al. CEA, CYFRA 21-1 and SCC in non-small cell lung cancer. Lung Cancer 1995; 13:169-76.
26. Arrieta O, Saavedra-Perez D, Kuri R, et al. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced nonsmall cell lung cancer: a prospective analysis. BMC Cancer 2009; 9:119.
27. Zaleska M, Szturmowicz M, Zych J, et al. Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival [in Polish]. Pneumonol Alergol Pol 2010; 78:14-20.
28. Reinmuth N, Brandt B, Semik M, et al. Prognostic impact of CYFRA 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002; 36:265-70. (Pubitemid 34497125)
29. Pujol JL, Boher JM, Grenier J, et al. CYFRA 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001; 31:221-31. (Pubitemid 32109238)
30. Hirashima T, Takada M, Komiya T, et al. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 1998; 18:4713-6. (Pubitemid 29042049)
31. Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1 and carcinoembryonic antigen in non-small cell lung carcinoma. Does the combined use of cytokeratin markers give any additional information? Cancer 1998; 82:1850-9. (Pubitemid 28208639)
32. Pujol J-L, Molinier O, Ebert W, et al. CYFRA21-1 is a prognostic determinant in non-small cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90:2097-105. (Pubitemid 38869712)
33. Díez M, Torres A, Maestro ML, et al. Prediction of survival and recurrence by serum and cytosolic levels of CEA, ca 125 and SCC antigens in resectable non-small cell lung cancer. Br J Cancer 1996; 73:1248-54. (Pubitemid 26162341)
34. Ando S, Kimura H, Iwai N, et al. Positive reactions for both CYFRA 21-1 and Ca125 indicate worst prognosis in non-small cell lung cancer. Anticancer Res 2003; 23:2869-74. (Pubitemid 36969825)
35. Okada M, Nishio W, Sakamoto T, et al. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg 2004; 78:1004-9. (Pubitemid 39164822)
36. Lai RS, Hsu HK, Lu JY, et al. CYFRA21-1 enzyme-linked immunosorbent assay. Evaluation as tumor marker in non-small cell lung cancer. Chest 1996; 109:995-1000.
37. Barlèsi F, Gimenez C, Torre JP, et al. Prognostic value of combination of CYFRA 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respiratory Med 2004; 98:357-62. (Pubitemid 38443696)
38. Vollmer RT, Govindan R, Graziano SL, et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cnacer: an early measure of response. Clin Cancer Res 2003; 9:1728-33. (Pubitemid 36554597)
39. Hamzaoui A, Thomas P, Castelnau O, et al. Usefulness of longitudinal evaluation of CYFRA 21-1 variations in advanced lung cancer monitoring. Lung Cancer 1997; 16:191-202. (Pubitemid 27215812)